501LBA LBA Orals: Phase 1 Expansion Results of IDE397, a First-in-class, Oral, MAT2A Inhibitor (mat2ai) in MTAP Deleted(del) Non-Small Cell Lung Cancer (NSCLC) and Urothelial Cancer (UC)

B. Herzberg, M. Johnson, C.G. Kim, A. Tolcher,J. Rodon,C. Mantia, J. Liu, A. Tripathi, L. Paz-Ares Rodriguez, T. De La Motte Rouge, C.M. Choi, J.Y. Han, L. Kwei, E. Liu,J. Sachdev, M. O’Quigley, M. White,D. Beaupre,H.R. Kim

European Journal of Cancer（2024）

引用 0|浏览0